ArticleJournal of the National Cancer Center2025
Global burden of female breast cancer: new estimates in 2022, temporal trend and future projections up to 2050 based on the latest release from GLOBOCAN.
Article in Journal of the National Cancer Center, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 105 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Comparative Study of Hypofractionated Adjuvant Radiotherapy in 2 Virsus 3 Weeks in Breast Cancer
Impact of Verbal Cueing in Multimodal Exercise Rehabilitation: A Retrospective Study in Breast Cancer Survivors Undergoing Radiation Therapy
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence and Influencing Factors of Anxiety and Depression in Patients With Breast Cancer: A Meta-Analysis.Actas espanolas de psiquiatria · 2026Pooled it
- Perception, Awareness, Knowledge, and Attitude (PAKA) Towards Breast Cancer in Ethiopia: A Systematic Review and Meta-Analysis.Journal of primary care & community healthPooled it
- Acceptance and commitment therapy improves the quality of life of breast cancer patients by reducing helplessness: a randomized controlled trial.BMC palliative care · 2026Trial
- The peripheral immune landscape of human breast cancer.Oncoimmunology · 2026Review
- Artesunate-loaded bovine serum albumin nanoplatform with metal-polyphenol network coating for ferroptosis-driven breast cancer therapy.International journal of pharmaceutics: X · 2026Article
- Molecular dynamics and predictive toxicity insights into theaflavin as a potential inhibitor of MMP-2 and MMP-9 in breast cancer.Toxicology reports · 2026Article
- Knowledge of early signs and risk factors, and attitude towards breast cancer among women in Dodoma, Tanzania: a community-based cross-sectional study.Future science OA · 2026Article
- Recent advancements in microtubule targeting agents for breast cancer: design strategies and pharmacological insights.Molecular diversity · 2026Review
- Development of ursolic acid-loaded cubosomal nanocarriers: enhanced dissolution, pharmacokinetics, bioavailability, and anticancer activity.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Localized immunotherapy via dissolving microneedles for the prevention of breast cancer recurrence.Drug delivery and translational research · 2026Review
- Superantigens in Cancer Immunotherapy: Mechanisms, Engineering Strategies, and Therapeutic Potential.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Article
- Integrin α3Cancer pathogenesis and therapy · 2026Article
- Synthesis, Structural Characterization, and Investigation of Biological Effects of Novel Benzothiazole-Triazole Derivatives Designed as AKT Kinase Inhibitors.Chemical biology & drug design · 2026Article
- Article
- Human biomarker navigator.iMeta · 2026Review
- Breast Cancer Knowledge and Screening Barriers Among Female University Students of Pakistan.International journal of environmental research and public health · 2026Article
- Algorithmic Prognostication in Female Oncofertility Counseling: Ethical Challenges of Bias, Autonomy, and Predictive Uncertainty.Healthcare (Basel, Switzerland) · 2026Review
- Venom-Derived Peptides in Breast Cancer: Pharmacological Mechanisms and Medicinal Chemistry-Guided Translational Development.Archiv der Pharmazie · 2026Review
- Real-world use of neratinib as extended adjuvant therapy in HER2-positive early-stage breast cancer: a multicentre study in mainland China and Hong Kong.Breast (Edinburgh, Scotland) · 2026Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) incidence and mortality vary significantly across countries, highlighting the need to update the global burden of female BC, including current trends and future projections. Methods: Data were sourced from GLOBOCAN 2022, including estimated new cases and deaths from BC across 21 United Nation (UN) regions and 185 countries, the age-standardized incidence rate (ASIR) and mortality rate (ASMR), the estimated annual percentage changes (EAPC), and demographic projections through 2050. The region-specific and country-specific BC burden for women of all ages and for young women (< 40 years old) was reorganized and re-plotted to highlight subgroup differences. Linear regression was used to explore the link between ASIR/ASMR and the human development index (HDI). Transitioning countries referred to those with low or medium HDI, while transitioned countries were those with high or very high HDI. Results: In 2022, an estimated 2.3 million new BC cases and 666,000 BC-related deaths occurred globally, accounting for 23.8 % and 15.4 % of all cancer cases and deaths in women, respectively. Regionally, Eastern Asia reported the highest number of cases (480,019, ASIR: 37.54/100,000), while South-Central Asia had the highest number of deaths (135,348, ASMR: 13.41/100,000). At the country level, China had the highest number of cases due to its large population, whereas India reported the highest number of deaths. ASIR for both overall and early-onset BC increased with HDI, while ASMR for early-onset BC decreased with HDI ( Conclusions: Breast cancer remains the leading cancer burden in women, particularly in transitioning countries. Addressing this growing burden requires urgent integration of primary prevention, early detection and high-quality treatment through multi-sectoral collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.